{"schema_version":"secwatch.filing_event.v1","accession":"0001829126-26-002020","form_type":"8-K","ticker":"NTHI","cik":"0001979414","company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","filed_at":"2026-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.924182+00:00","generated_at":"2026-05-15T19:02:35.391721+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"NeOnc reports Phase 1 dose-escalation results for NEO212; RP2D set at 610 mg","bullets":["MTD reached at 810 mg (Cohort 5) with second DLT; dose escalation halted.","Recommended Phase 2 Dose (RP2D) set at 610 mg; Phase 2a metastasis start at 400 mg.","Early efficacy signals: partial response in recurrent GBM (~60% tumor reduction after 21 cycles) and stable disease in brain metastasis.","No clinically meaningful myelosuppression; 39x lower AIC vs TMZ indicating lower toxicity.","Type B FDA meeting to be requested for accelerated approval pathway."],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-26-002020","json":"https://secwatch.observer/filing/0001829126-26-002020.json","markdown":"https://secwatch.observer/filing/0001829126-26-002020.md","text":"https://secwatch.observer/filing/0001829126-26-002020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1979414/000182912626002020/0001829126-26-002020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1979414/000182912626002020/neonctechnologies_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T19:02:35.391721+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}